MAP2K7 and cancer: Thus, identification and understanding of the mechanisms of resistance to BRAF or MEK inhibitors in BRAF mutant cancers could not only lead to strategies to overcome established resistance, but may yield a means by which to prevent resistance from emerging and to prolong the clinical response to therapy.